O'Connor Padraig Andrew 4

What Happened

• Padraig Andrew O'Connor, EVP, Global Operations of Boston Scientific, reported derivative activity and awards on Feb 12, 2026. The Form 4 shows an exercise/conversion of 1,058 derivative shares (code M) and a tax/withholding disposition of 457 shares at $74.12 each, totaling $33,873 (code F). The filing also reports awards/grants of 5,059 and 11,939 derivative units (code A), each reported at $0 per share.

Key Details

• Transaction date: February 12, 2026; Form 4 filed February 17, 2026 (within typical two business-day reporting window given the Feb 16 holiday).
• Exercise/conversion: 1,058 derivative shares (code M) reported at $0 per share.
• Tax withholding: 457 shares withheld (code F) at $74.12 = $33,873 to satisfy tax obligations.
• Awards/grants: 5,059 and 11,939 derivative units reported as acquired (code A) at $0 per share.
• Footnotes:
  • F1: Reported restricted stock units (RSUs) represent a commitment to issue one share per unit.
  • F2: The 5,059 award vests in four equal annual installments beginning Feb 12, 2025.
  • F3: The 11,939 award vests in four equal annual installments beginning Feb 12, 2027.
  • F4: A grant of options (vesting in four equal annual installments beginning Feb 12, 2027) is referenced.
• Shares owned after the transaction are not provided in the information supplied in this summary.

Context

• The 457-share disposition is a tax withholding event (common when RSUs vest or options are exercised) rather than an open-market sale — the shares were retained by the issuer to cover taxes, not necessarily sold on the market by the insider.
• The filings are mostly awards and derivative conversions (not new open-market purchases), so they reflect compensation-related equity activity rather than an outright buy/sell decision by the insider.
• No indication in the supplied data that this is a 10% owner transaction or a 10b5-1 plan; the activity appears to be routine compensation vesting/exercise and associated tax withholding.